Effect of Dagliazine on β2 Microglobulin in Patients With Early Diabetic Nephropathy
Objective To investigate the effects of dagliprazin on β2-microglobulin(β2-MG)in patients with early diabetic nephropathy(DN).Methods A total of 100 patients with early diabetic nephropathy in Maoming People's Hospital from June 2021 to December 2022 were selected as the study objects,with 50 cases in each group.Two groups of blood glucose indicators before and after treatment:fasting plasma glucose(FPG),2-hour postprandial glucose(2 hPG),glycated hemoglobin A1c(HbA1c),body mass index(BMI),and blood lipid indicators(total cholesterol(TC),low density lipoprotein cholesterol(LDL-C),and triglycerides(TG).Renal function indicators[β2-MG,cystatin C(CysC),serum creatinine(Scr)]and incidence of adverse reactions were compared.Results After treatment,the levels of FPG,2 hPG and HbAlc in two groups were lower than before treatment,and the test group was lower than the control group(P<0.05).After treatment,the BMI of test group was lower than that of control group(P<0.05).After treatment,TC,LDL-C and TG in both groups were lower than before treatment,and the experimental group was lower than the control group(P<0.05).After treatment,the levels of serum β2-MG,CysC and Scr in two groups were lower than before treatment,and those in test group were lower than those in control group(P<0.05).The total incidence of adverse reactions in the experimental group was 6.00%(3/50),while in the control group was 8.00%(5/50),with no statistically significant difference(χ2=0.136,P=0.712).Conclusion Daglipzin in the treatment of early DN patients can improve blood glucose control effect,reduce serum β2-MG,CysC,Scr levels,protect patients'kidney function,and has a certain fat and weight reduction effect,with high safety.
dagliazinediabetic nephropathyβ2 microglobulincystatin Cserum creatininebody mass index
NETL
NSTL
万方数据
